Griffith University’s Institute for Glycomics has developed a groundbreaking, combination vaccine that may finally beat Streptococcus A infections. Human trials are set to begin as early as next year.
Griffith launches human trials for a vaccine against Streptococcus A, the germ that causes rheumatic fever.
Griffith University researchers have discovered a genetic switch in a common bacterium that helps defend itself against the human body’s...
It’s a little known bacterium with a global reach and its presence in the human system can go unnoticed for...
Griffith University has reached the milestone achievement of raising $100 million of its $125 million target as part of The Campaign to Create a Brighter Future for All.
Strep A (Streptococcus pyogenes) is a major cause of infection-related deaths, leading to over 500,000 fatalities annually. Developing countries, Indigenous populations, and vulnerable groups face the greatest risks. A potential vaccine, developed by Professor Michael Good's team at Griffith University, is undergoing human trials and shows promise in fighting multiple Strep A strains.
As Streptococcus A cases continue to be prevalent in Queensland and internationally, a new nasal vaccine could provide long-term protection from the deadly bacteria.
Griffith University researchers are on the brink of a technological breakthrough in vaccine development with a possible new vaccine modality.
Griffith University researchers have unlocked one of the secrets as to why some forms of Strep A are associated with severe invasive infection.
A team of international scientists from Griffith University and the University of Alberta are about to start human clinical trials for a Strep A vaccine they hope will induce long-lasting immunity against the deadly pathogen which kills more than 500,000 people each year.
